Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results
Select data models

Selected data models

You must log in to select data models for download or further analysis.

14 Search results.

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – On- Treatment

- 11/18/21 - 9 forms, 1 itemgroup, 3 items, 1 language

Itemgroup: Subject details

Study documentation part: On- Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3

On-Treatment 1

15 itemgroups 84 items

On-Treatment 2

13 itemgroups 62 items

On-Treatment 4

12 itemgroups 62 items

On-Treatment 6

12 itemgroups 62 items

On-Treatment 7

13 itemgroups 67 items

On-Treatment 8

13 itemgroups 67 items

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Pre-Treatment - Previous and current therapies for leukemia

- 9/20/21 - 8 forms, 4 itemgroups, 10 items, 1 language

Itemgroups: PREVIOUS AND CURRENT THERAPIES FOR LEUKEMIA, STEM CELL TRANSPLANT, PRIOR RADIOTHERAPY FOR LEUKEMIA, EXTERNAL DATA TRACKING

Study documentation part: Pre-Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.

Medical tests and examinations

5 itemgroups 43 items

Pre- treatment status

2 itemgroups 10 items

Pre- Treatment events

3 itemgroups 18 items

Previous and current medications

1 itemgroup 3 items

General Medical History

5 itemgroups 37 items

Imatinib Mesylate

3 itemgroups 13 items

Eligibility Philadelphia Positive Acute Lymphoblastic Leukemia NCT00199186

- 7/31/17 - 1 form, 2 itemgroups, 16 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL); ODM derived from: https://clinicaltrials.gov/show/NCT00199186

Eligibility Leukemia, Myeloid, Philadelphia-Positive NCT00037882

- 6/19/16 - 1 form, 2 itemgroups, 19 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron; ODM derived from: https://clinicaltrials.gov/show/NCT00037882

Visit 9 (24 Months) Ponderosa CML ZKSJ0083 - Visit 9 (24 Months)

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Visit 9 (24 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 8 (21 Months) Ponderosa CML ZKSJ0083 - Visit 8 (21 Months)

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Visit 8 (21 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Cancellation Visits Ponderosa CML ZKSJ0083 - Cancellation Visits

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Cancellation Visits.Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 3 (6 Months) Ponderosa CML ZKSJ0083 - Visit 3 (6 Months)

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Visit 3 (6 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 4 (9 Months) Ponderosa CML ZKSJ0083 - Visit 4 (9 Months)

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Visit 4 (9 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 7 (18 Months) Ponderosa CML ZKSJ0083 - Visit 7 (18 Months)

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Visit 7 (18 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 5 (12 Months) Ponderosa CML ZKSJ0083 - Visit 5 (12 Months)

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Visit 5 (12 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Visit 6 (15 Months) Ponderosa CML ZKSJ0083 - Visit 6 (15 Months)

- 3/20/16 - 1 form, 5 itemgroups, 61 items, 1 language

Itemgroups: Patient status, Blood pressure, Laboratory parameters, Treatment, Treatment Response

Study part: Visit 6 (15 Months).Observational study on CML patients in any phase treated with ponatinib (Iclusig®) at any dose. Principal Investigator Prof. Dr. A. Hochhaus.

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.